SenzaGen performs largest test order for GARD®skin – valued at approximately SEK 1m
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SenzaGen has been selected to test substances for a new customer, a world leader in the chemicals industry, for a total value of approximately SEK 1 million. The order, which is the single largest for GARD®skin and also the largest from a chemicals company, was received at the end of the second quarter and will be completed in the third quarter of 2022 at SenzaGen’s GLP-certified laboratory in Lund.
The customer, who has its headquarters in the US, aims to use GARD®skin to obtain more detailed information about the skin sensitizing effect of substances traditionally considered difficult to test with other previous generations of test methods, thus expanding its reference library.
“We are seeing a strong increased demand for our tests and it is highly gratifying that more customers are choosing to place larger test orders with us, this time a world leader in chemicals with global operations. This serves as further confirmation of interest in GARD® skin’s unique capability to be used for and generate more data on difficult-to-test substances. With GARD®skin, we meet a skin sensitization need not covered by any other available tests”, says Peter Nählstedt, President and CEO of SenzaGen.
With high reliability, GARD®skin test results help product development companies and producers ensure that the products they bring to market are free of allergens, enabling them, when needed, to prove this in their product filings. GARD®skin has been approved by the OECD as a test guideline for non-animal skin sensitization since 30 June 2022.